Gwenn Hansen Nurix Therapeutics, Inc. (NRIX) insider trading activity

NRIX Quotes by TradingView

Gwenn Hansen is Chief Scientific Officer of Nurix Therapeutics, Inc.. Currently has a direct ownership of 50,670 shares of NRIX, which is worth approximately $1.01 Million. The most recent transaction as insider was on Oct 30, 2024, when has been sold 3,437 shares (Common Stock) at a price of $24.3 per share, resulting in proceeds of $83,519. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 50.7K
12.23% 3M change
51.12% 12M change
Total Value Held $1.01 Million

Gwenn Hansen Transaction History

Date Transaction Value Shares Traded Shares Held Form
Oct 30 2024
SELL
Open market or private sale
$83,519 $24.3 p/Share
3,437 Reduced 6.35%
50,670 Common Stock
Oct 30 2024
BUY
Exercise of conversion of derivative security
-
8,957 Added 14.2%
54,107 Common Stock
Jul 30 2024
SELL
Open market or private sale
$70,443 $20.67 p/Share
3,408 Reduced 7.02%
45,150 Common Stock
Jul 30 2024
BUY
Exercise of conversion of derivative security
-
8,957 Added 15.57%
48,558 Common Stock
Apr 30 2024
SELL
Open market or private sale
$24,164 $12.04 p/Share
2,007 Reduced 4.82%
39,601 Common Stock
Apr 30 2024
BUY
Exercise of conversion of derivative security
-
5,206 Added 11.12%
41,608 Common Stock
Jan 30 2024
SELL
Open market or private sale
$18,648 $7.99 p/Share
2,334 Reduced 6.03%
36,402 Common Stock
Jan 30 2024
BUY
Exercise of conversion of derivative security
-
5,207 Added 11.85%
38,736 Common Stock
Oct 31 2023
SELL
Open market or private sale
$8,491 $5.2 p/Share
1,633 Reduced 4.64%
33,529 Common Stock
Oct 30 2023
BUY
Exercise of conversion of derivative security
-
5,207 Added 12.9%
35,162 Common Stock
Jul 31 2023
SELL
Open market or private sale
$18,180 $9.65 p/Share
1,884 Reduced 5.92%
29,955 Common Stock
Jul 30 2023
BUY
Exercise of conversion of derivative security
-
5,207 Added 14.06%
31,839 Common Stock
May 01 2023
SELL
Open market or private sale
$11,223 $9.88 p/Share
1,136 Reduced 4.09%
26,632 Common Stock
Apr 30 2023
BUY
Exercise of conversion of derivative security
-
3,206 Added 10.35%
27,768 Common Stock
Jan 30 2023
SELL
Open market or private sale
$16,633 $11.78 p/Share
1,412 Reduced 5.78%
23,009 Common Stock
Jan 30 2023
BUY
Exercise of conversion of derivative security
-
3,207 Added 11.61%
24,421 Common Stock
Oct 31 2022
SELL
Open market or private sale
$15,005 $12.88 p/Share
1,165 Reduced 5.21%
21,214 Common Stock
Oct 30 2022
BUY
Exercise of conversion of derivative security
-
3,207 Added 12.53%
22,379 Common Stock
Aug 01 2022
SELL
Open market or private sale
$18,585 $15.67 p/Share
1,186 Reduced 5.83%
19,172 Common Stock
Jul 30 2022
BUY
Exercise of conversion of derivative security
-
3,207 Added 13.61%
20,358 Common Stock
May 02 2022
SELL
Open market or private sale
$12,902 $11.75 p/Share
1,098 Reduced 6.02%
17,151 Common Stock
Apr 30 2022
BUY
Exercise of conversion of derivative security
-
3,206 Added 14.94%
18,249 Common Stock
Jan 03 2022
SELL
Open market or private sale
$52,939 $28.96 p/Share
1,828 Reduced 11.41%
14,197 Common Stock
Jan 03 2022
BUY
Exercise of conversion of derivative security
$15,392 $8.42 p/Share
1,828 Added 10.24%
16,025 Common Stock
Dec 01 2021
SELL
Open market or private sale
$11,652 $29.13 p/Share
400 Reduced 2.74%
14,197 Common Stock
GH

Gwenn Hansen

Chief Scientific Officer
San Francisco, CA

Track Institutional and Insider Activities on NRIX

Follow Nurix Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NRIX shares.

Notify only if

Insider Trading

Get notified when an Nurix Therapeutics, Inc. insider buys or sells NRIX shares.

Notify only if

News

Receive news related to Nurix Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on NRIX